Abstract:Heart failure with preserved ejection fraction (HFpEF) is now the dominant form of newly diagnosed heart failure. HFpEF is also a form of heart failure for which there is no specific evidence-based therapy. With a dire prognosis (1-year mortality rate after first hospitalization is near 30%), the unmet clinical need is enormous. The complexity and heterogeneity of HFpEF syndrome subphenotypes have generated diagnostic controversy and so far, thwarted attempts to define pathogenesis. This phenotypic variability reflects the constellation of comorbidities, including hypertension, obesity, diabetes mellitus, cardiac hypertrophy, and renal involvement with which HFpEF is associated. Presumably these various comorbidities arise from interactions between underlying genetic disease predispositions and exposure to a range of environmental stressors. Beyond the discriminator of ejection fraction, HFpEF is considered a fundamentally different disease state when contrasted with heart failure with reduced ejection fraction (HFrEF). In efforts to unveil HFpEF disease mechanistic insight, there have been urgent calls for the development of animal models that might better recapitulate the complex phenotypes observed clinically. 1 Overall, the response to these calls in developing novel and relevant animal models has been disappointing. Only now, after a considerable lag, new findings at the bench are delivering important HFpEF revelations and suggest that the time is right for innovative approaches to move forward. Here we make the case that new experimental strategies can be used to explore how human polygenicity might interact with environmental stressors to drive clinical phenotypic variability in HFpEF. Why Have Conventional HFrEF Strategies Failed for HFpEF? Experimentally, much of the effort invested to date in attempting to understand the mechanistic bases of HFpEF has relied on manipulation of animal models that have been productive in characterizing HFrEF but are of limited utility in understanding HFpEF. These models frequently involve neurohormonal disturbances, particularly those linked with the renin-angiotensin-aldosterone axis or related to progressive metabolic diabetic diseases, and comprise genetic, surgical, and pharmacologic interventions. 2 Unsurprisingly, a distinctive HFpEF functional or structural phenotype has not emerged from these studies. Clinically, HFrEF therapies deliver some symptomatic benefit in the HFpEF setting but not mortality gain. While a HFpEF state involving neuroendocrine complication is partially responsive to a HFrEF intervention, there are key differences in these disease types. A transition from HFpEF to HFrEF is not typical in human HFpEF. Thus, fundamental HFpEF mechanistic insights have been difficult to glean from animal models that largely reflect a temporary stage of ejection fraction maintenance during the trajectory to an underlying HFrEF end point. These approaches have not yet uncovered an intrinsically different HFpEF cardiomyocyte. The HFrEF cardiomyocyte is characterized as a failing contractile unit, depleted of systolic activator Ca 2+ reserves, whereas reduced Ca 2+ availability does not feature as a HFpEF cardiomyocyte phenotype. HFrEF is defined by systolic deficit, but HFpEF does not simply equate to diastolic dysfunction. New Cellular Mechanistic Findings Require New Conceptual Approaches There is increasing recognition that the cardio-centric view of HFrEF does not fit HFpEF. HFpEF is emerging as a multisystem inflammatory metabolic condition, where meta-inflammation is understood to be driven by excess adiposity linked with imbalance of nitric oxide (NO) levels. Hypertension, also associated with generalized disruption in NO metabolism and bioavailability, is commonly observed as a comorbid component. Recently, an approach that combined these 2 phenotypic liabilities in a mouse model has shown convincingly that a multicomponent pathogenesis can effectively recapitulate HFpEF pathology, even though the individual insults alone did not. Genetically normal mice subjected to a 2-hit insult comprising metabolic stress (high dietary fat) and NO-induced mechanical stress (suppression of constitutive NO synthases) exhibited a robust HFpEF phenotype. 3 Interestingly, molecular interrogation of the phenotype expression identified disruption of the unfolded protein response. The unfolded protein response is known to be coregulated with autophagy in a range of disease states. This finding suggests that although phenotypically diverse, HFpEF conditions may have common convergent downstream cellular pathology. While this particular dual insul -Abstract Truncated-

HFpEF-Time to Explore the Role of Genetic Heterogeneity in Phenotypic Variability: New Mechanistic Insights Offer Promise for Personalized Therapies.

Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats.

Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models

Integrated systems biology identifies disruptions in mitochondrial function and metabolism as key contributors to heart failure with preserved ejection fraction (HFpEF)

Distinguishing pathophysiological features of heart failure with reduced and preserved ejection fraction: A comparative analysis of two mouse models

Pathophysiological insights into HFpEF from studies of human cardiac tissue

Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials

Using Model‐Based Analysis and Physiology‐Informed Machine Learning to Refine the Stratification of Phenotypes in Heart Failure

Pathobiological characterization of pulmonary hypertension associated with heart failure with preserved ejection fraction

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach

Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype

Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery

Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models

Cellular and molecular pathobiology of heart failure with preserved ejection fraction

Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction

Mouse Model of Heart Failure With Preserved Ejection Fraction Driven by Hyperlipidemia and Enhanced Cardiac Low‐Density Lipoprotein Receptor Expression

Benchmarking pre-clinical heart failure with preserved ejection fraction models: can we do better?

Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents

Advances in extracardiac mechanisms for heart failure with preserved ejection fraction

Mimicking Metabolic Disturbance in Establishing Animal Models of Heart Failure With Preserved Ejection Fraction